Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience

Conclusion t-CMML comprises a small portion of all CMML cases (11%). Median OS in the dn-CMML group was longer than in the t-CMML group but LT seemed to be similar in terms of incidence and time to occurrence. Additional studies are needed to confirm our results. Micro-Abstract Treatment-related (t-) chronic myelomonocytic leukemia (CMML) carry a worse clinical outcome than de novo (dn-) CMML (dn-CMML). Most t-CMML patients had received previous chemotherapy exposure. Patients with t-CMML had a shorter median overall survival than those with dn-CMML but similar time to leukemic transformation. Patients with t-CMML have a poor prognosis and should be considered for investigational treatment.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research